RepliCel Life Sciences Inc. announced a non-brokered private placement of up to 10,500,000 units at an issue price of CAD 0.10 per unit for gross proceeds of CAD 1,050,000 on January 26, 2023. Each unit consists of one common share of the company and one-half of one share purchase warrant. Each whole warrant entitles the holder thereof to purchase one additional share of the company at a price of CAD 0.20 per share for a period of four years from closing of the offering.

The offering is subject to the approval of the TSX Venture Exchange. Insiders may participate in the offering. Finders' fees may be payable in connection with the offering in accordance with the policies of the exchange.

All securities issued in connection with the offering will be subject to a statutory hold period expiring four months and one day after closing of the offering. Completion of the offering is subject to the approval of the exchange.